Off-Pump Coronary Artery Bypass Grafting: Technical Evolution, Current Evidence, and Barriers to Universal Adoption

Abstract

Off-pump coronary artery bypass grafting (OPCAB) represents one of the most significant technical innovations in contemporary cardiac surgery. Developed as an alternative to conventional on-pump coronary artery bypass grafting (ONCAB), OPCAB avoids cardiopulmonary bypass and its associated systemic inflammatory response, aiming to reduce perioperative morbidity and improve recovery. Over the past three decades, advances in stabilization devices, intracoronary shunts, anesthetic management, and surgical training have refined the procedure, making it safer and more reproducible. Despite these developments, OPCAB adoption remains inconsistent worldwide, reflecting ongoing debate about its relative benefits and limitations. Evidence from randomized controlled trials, meta-analyses, and large registries suggests that OPCAB achieves comparable early mortality to ONCAB, with potential advantages in reducing renal dysfunction, neurocognitive decline, and perioperative bleeding. These benefits appear most pronounced in high-risk subgroups, including elderly patients and those with significant comorbidities. However, concerns persist regarding long-term graft patency, completeness of revascularization, and variability in outcomes depending on surgeon experience and institutional expertise. Cost-effectiveness analyses have suggested potential resource savings, but these are offset by training requirements and the technical complexity of the procedure. Global practice variation highlights the influence of surgical culture, guideline ambiguity, and institutional resources. Barriers to universal adoption include technical challenges, inconsistent long-term outcomes, and limited exposure in training programs. In the future, robotic and minimally invasive OPCAB, as well as hybrid revascularization strategies, may expand its role. This review synthesizes current evidence, explores barriers to widespread implementation, and outlines future directions for integrating OPCAB into balanced, evidence-based clinical practice.

1. Introduction

Coronary artery bypass grafting (CABG) remains the most frequently performed cardiac surgical procedure worldwide and is considered the gold standard for patients with multivessel coronary artery disease—particularly those with diabetes, left main involvement, or a high SYNTAX score, which integrates anatomical and clinical complexity to guide contemporary revascularization strategies [1]. Conventional CABG performed with cardiopulmonary bypass (ONCAB) provides a motionless and bloodless surgical field, facilitating precise anastomoses, but is associated with systemic inflammatory responses, renal dysfunction, neurocognitive decline, and coagulopathy [2,3]. These complications prompted the development of off-pump coronary artery bypass grafting (OPCAB), performed on the beating heart without cardiopulmonary bypass, as a strategy to mitigate perioperative morbidity.

The resurgence of OPCAB in the 1990s was enabled by advances in mechanical stabilization devices, intracoronary shunts, and anesthetic techniques that allowed surgeons to perform coronary anastomoses on a beating heart with acceptable precision [4,5]. Early reports suggested reductions in perioperative complications, shorter hospital stays, and lower transfusion requirements compared with ONCAB [6]. However, concerns regarding incomplete revascularization, technical complexity, and long-term graft patency tempered enthusiasm for widespread adoption.

Despite three decades of experience, OPCAB adoption remains variable across regions. In some countries, particularly in Asia, OPCAB accounts for a substantial proportion of CABG procedures, whereas in North America and Europe its use is limited (Figure 1) [7]. This variation reflects differences in surgical training, institutional resources, and guideline recommendations. The ongoing debate underscores the need for a balanced, evidence-based appraisal of OPCAB, integrating technical evolution, clinical outcomes, and barriers to universal adoption.

The literature for this review was identified through a structured search of PubMed, Embase, and the Cochrane Library using combinations of the following terms: “off-pump coronary artery bypass,” “OPCAB,” “on-pump CABG,” “coronary revascularization,” “clinical outcomes,” and “graft patency.” Additional references were identified through manual screening of bibliographies from key trials and meta-analyses. Approximately 180 manuscripts—including randomized trials, meta-analyses, large registries, and contemporary observational studies—were reviewed for inclusion.

2. Technical Principles and Evolution

2.1. Surgical Techniques and Stabilization Devices

The cornerstone of OPCAB is the ability to perform coronary anastomoses on a beating heart with precision and safety. Early attempts were limited by excessive cardiac motion and hemodynamic instability, but the introduction of mechanical stabilizers revolutionized the field [8]. Modern stabilizers, such as suction-based and compression devices, allow localized immobilization of the target coronary segment while maintaining global cardiac function. Intracoronary shunts further facilitate bloodless fields, reducing ischemia during anastomosis [9].

Advances in positioning techniques, including pericardial traction sutures and heart positioning devices, have expanded access to posterior and lateral vessels, enabling more complete revascularization [10]. These innovations have reduced the technical barriers that initially limited OPCAB to anterior vessels. The refinement of stabilizers and positioning systems has been critical in broadening the applicability of OPCAB to multivessel disease.

Despite these advances, technical complexity remains a challenge. OPCAB requires meticulous planning of graft sequence, careful management of hemodynamics, and precise coordination between surgeons and anesthesiologists. The learning curve is steep, with outcomes strongly correlated to surgeon experience and institutional volume [11]. As such, stabilization devices are not merely adjuncts but essential enablers of safe and reproducible OPCAB.

2.2. Anaesthetic and Perfusion Considerations

Anesthetic management in OPCAB differs significantly from ONCAB, as the absence of cardiopulmonary bypass necessitates continuous hemodynamic stability throughout the procedure. Anesthesiologists must anticipate hemodynamic shifts during cardiac displacement and stabilization, employing strategies such as volume loading, vasopressor support, and transesophageal echocardiography monitoring [12].

Ventilation strategies are also critical, as lung volume reduction during heart positioning can impair oxygenation. Low tidal volume ventilation and careful adjustment of positive end-expiratory pressure are often required [13]. In addition, anesthetic agents must balance myocardial protection with rapid recovery, favoring short-acting drugs that allow prompt postoperative extubation.

Perfusion considerations extend to the avoidance of systemic inflammatory responses associated with cardiopulmonary bypass. OPCAB patients typically demonstrate reduced cytokine release, lower complement activation, and attenuated coagulation disturbances compared with ONCAB [14]. These physiological advantages may contribute to observed reductions in renal dysfunction and neurocognitive decline in selected populations.

The anesthetic team plays a pivotal role in OPCAB success, requiring close collaboration with the surgeon to anticipate hemodynamic challenges and optimize myocardial perfusion. This interdependence underscores the multidisciplinary nature of OPCAB and the need for specialized training across the operative team.

2.3. Advances in Training and Simulation

The technical demands of OPCAB have driven innovations in surgical training and simulation. Traditional apprenticeship models proved insufficient for mastering the complex coordination required, leading to the development of dedicated OPCAB training curricula [15]. These programs emphasize stepwise skill acquisition, beginning with anterior vessel grafting and progressing to multivessel revascularization.

Simulation platforms, including beating-heart models and virtual reality systems, have emerged as valuable tools for skill development. These allow trainees to practice stabilization, positioning, and anastomotic techniques in controlled environments without patient risk [16]. Studies have demonstrated that simulation training accelerates proficiency, reduces intraoperative errors, and shortens the learning curve [17].

Institutional experience remains a critical determinant of outcomes. High-volume centers consistently report superior results compared with low-volume institutions, reflecting the cumulative expertise of surgical teams [18]. This has prompted calls for regionalization of OPCAB training and the establishment of centers of excellence to ensure consistent quality.

Future directions in training include integration of robotic platforms and hybrid revascularization strategies into curricula. As OPCAB evolves, simulation and structured training will remain essential to overcoming technical barriers and ensuring safe, reproducible outcomes across diverse practice settings.

3. Clinical Outcomes: Evidence from Trials and Registries Comparing OPCAB vs. ONCAB

3.1. Early vs. Late Outcomes: Mortality, Renal Function, and Neurological Outcomes

The evidence comparing OPCAB and ONCAB derives from both randomized controlled trials and large observational registries. Major randomized trials—including ROOBY, CORONARY, and GOPCABE—provide high-quality comparative data [19,20,21], while contemporary observational studies have increasingly adopted propensity score–based methods such as matching, weighting, and stratification to reduce confounding related to baseline risk differences. Together, these complementary study designs form the foundation of current understanding of early and long-term outcomes following OPCAB.

Early outcomes following OPCAB have been extensively studied in randomized controlled trials (RCTs) and registries. Most large RCTs, including ROOBY (1.6% OPCAB vs. 1.2% ONCAB), CORONARY (2.5% OPCAB vs. 2.5% ONCAB), and GOPCABE (2.6% OPCAB vs. 2.8% ONCAB), demonstrated no significant difference in 30-day mortality between OPCAB and ONCAB [19,20,21]. However, observational data suggest that OPCAB may confer modest reductions in perioperative complications, particularly in high-risk patients.

Renal outcomes have been a focus of comparative studies, given the association between cardiopulmonary bypass and acute kidney injury. In major randomized trials, renal dysfunction rates were similar—for example, 7.8% OPCAB vs. 5.8% ONCAB in the ROOBY trial [19], 1.2% OPCAB vs. 1.4% ONCAB in CORONARY trial [20], and 8.5% OPCAB vs. 8.8% ONCAB in GOPCABE trial [21]. On the other hand, several analyses have reported lower rates of postoperative renal dysfunction with OPCAB, especially in patients with pre-existing chronic kidney disease [22]. This advantage appears most pronounced in elderly and comorbid populations, where renal reserve is limited.

Neurological outcomes, including stroke and cognitive decline, have also been investigated. OPCAB has been associated with reduced perioperative stroke rates in several analyses, likely due to avoidance of aortic manipulation and embolic phenomena [23]. On the contrary, contemporary randomized trials demonstrate comparable stroke rates with no advantage for OPCAB—for example, 1.5% vs. 2.1% in CORONARY, 2.2% vs. 2.7% in GOPCABE, and 2.0% vs. 2.4% in ROOBY. Cognitive outcomes are more nuanced; while some studies and meta-analyses suggest attenuated early neurocognitive decline with OPCAB, others report no sustained long-term difference compared with ONCAB [24].

Late outcomes, including survival at 5–10 years, generally show equivalence between OPCAB and ONCAB, though some trials report higher rates of repeat revascularization in OPCAB cohorts [23,25]. These findings highlight the balance between short-term morbidity reduction and long-term durability.

3.2. Subgroup Analyses: High-Risk Patients, Elderly, Comorbidities

Subgroup analyses have consistently demonstrated that OPCAB may offer particular benefits in high-risk populations. Elderly patients, who are more susceptible to complications from cardiopulmonary bypass, often experience reduced perioperative morbidity with OPCAB [26]. Similarly, patients with significant comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, or peripheral vascular disease may benefit from the less invasive physiological profile of OPCAB [22,27,28].

Diabetic patients represent another important subgroup. Some registry data suggest improved perioperative outcomes with OPCAB in diabetics, though long-term survival and graft patency remain comparable to ONCAB [29]. Patients with severe left ventricular dysfunction have also been studied, with mixed results: while OPCAB may reduce perioperative complications, concerns about completeness of revascularization persist [30].

These subgroup findings underscore the importance of patient selection. OPCAB may not be universally superior, but in carefully chosen populations it can provide meaningful reductions in morbidity without compromising survival.

3.3. Meta-Analyses and Guideline Perspectives

Meta-analyses pooling RCTs and observational studies have provided nuanced insights into OPCAB outcomes. Several analyses report reduced perioperative stroke and renal dysfunction with OPCAB, but no consistent survival advantage [22,23]. Importantly, heterogeneity in trial design, surgeon expertise, and patient populations complicates interpretation.

Guideline perspectives reflect this uncertainty. The European Society of Cardiology and American Heart Association guidelines acknowledge OPCAB as a reasonable alternative in selected patients, particularly those at high risk for complications from cardiopulmonary bypass [31,32]. However, they stop short of recommending universal adoption, citing concerns about incomplete revascularization and variable long-term outcomes.

Thus, while meta-analyses and guidelines recognize potential benefits, they emphasize individualized decision-making and the importance of surgical expertise.

3.4. Graft Patency and Completeness of Revascularization

Long-term graft patency remains a central concern in OPCAB. Angiographic studies have reported slightly lower patency rates in OPCAB compared with ONCAB, particularly in multivessel disease [33]. This may reflect technical challenges in accessing posterior vessels and ensuring complete revascularization.

Incomplete revascularization has been cited as a limitation of OPCAB, with some trials reporting lower rates of multivessel grafting compared with ONCAB [19]. However, experienced centers have demonstrated comparable completeness of revascularization, highlighting the role of surgeon expertise [18].

The debate over graft patency underscores the tension between short-term morbidity reduction and long-term durability. Ensuring technical excellence and adequate training is critical to addressing these concerns.

3.5. Cost-Effectiveness and Resource Utilization

Economic analyses have explored the cost implications of OPCAB. Reduced transfusion requirements, shorter intensive care stays, and lower complication rates suggest potential cost savings [34]. However, these advantages may be offset by longer operative times, intraoperative conversion, specialized equipment, and the need for highly trained surgical teams.

Registry data from high-volume centers indicate that OPCAB can be cost-effective when performed by experienced teams, particularly in high-risk populations [18]. Conversely, in low-volume institutions, variability in outcomes may negate economic benefits.

Ultimately, cost-effectiveness is closely tied to institutional expertise and patient selection. OPCAB may provide resource savings in appropriate contexts, but universal adoption without adequate training infrastructure could increase variability and costs.

4. Global Variation in Practice

4.1. Regional Trends and Adoption Rates

The adoption of OPCAB has varied significantly across regions, reflecting differences in surgical philosophy, healthcare infrastructure, and patient demographics. In Asia—particularly India, Korea, and Japan—OPCAB has achieved widespread use, with some centers reporting that more than half of CABG procedures are performed off-pump [35,36]. In India, for example, several high-volume institutions routinely perform 50–60% of CABG procedures using OPCAB techniques, while Japanese and Korean centers similarly report >50% utilization in selected hospitals [35,36]. This trend has been driven by resource constraints, where avoiding cardiopulmonary bypass reduces costs and perioperative morbidity, making OPCAB attractive in high-volume, cost-sensitive environments.

In contrast, adoption in North America and Europe has been more limited. Data from the Society of Thoracic Surgeons (STS) registry indicate that OPCAB accounts for less than 20% of CABG procedures in the United States, with national estimates ranging from 15 to 18% depending on the reporting period [37]. European practice patterns are similarly conservative, with most centers favoring ONCAB due to concerns about graft patency and completeness of revascularization. Nonetheless, select high-volume institutions in the UK, Germany, and Italy have demonstrated excellent outcomes with OPCAB, underscoring the importance of institutional expertise rather than regional norms [11].

Latin America and the Middle East present intermediate adoption rates, with variability depending on institutional resources and surgeon training. In Brazil, national registry data indicate that OPCAB represents approximately 13–20% of CABG procedures, with favorable outcomes reported in large patient cohorts [38,39]. This reflects both economic considerations and a strong tradition of surgical innovation in the region.

Overall, global adoption of OPCAB remains heterogeneous, with high penetration in Asia and parts of Latin America, but more limited uptake in North America and Europe. These differences highlight the interplay between healthcare economics, surgical culture, and institutional expertise.

4.2. Influence of Surgical Training and National Guidelines

Surgical training has played a pivotal role in shaping OPCAB adoption. In regions where OPCAB is integrated into residency and fellowship curricula, such as India and Brazil, surgeons gain early exposure to beating-heart techniques, facilitating widespread practice [40]. Conversely, in North America and Europe, training programs often emphasize ONCAB, with limited opportunities for OPCAB proficiency. This disparity could contribute to regional differences in adoption and outcomes.

Institutional culture further shapes adoption. High-volume centers with dedicated OPCAB programs report superior outcomes, while low-volume institutions often struggle with variability. This has led to calls for regionalization of OPCAB training and the establishment of centers of excellence to ensure consistent quality [18].

Ultimately, surgical training and guideline perspectives are central to the global variation in OPCAB practice. Regions that prioritize structured training and provide clear guideline support demonstrate higher adoption rates and better outcomes, while regions with limited exposure remain cautious.

5. Barriers to Universal Adoption

5.1. Technical Complexity

One of the most frequently cited barriers to OPCAB adoption is its technical complexity (Figure 2). Performing coronary anastomoses on a beating heart requires advanced surgical dexterity, precise stabilization, and continuous hemodynamic management [41]. The steep learning curve means that outcomes are strongly correlated with surgeon experience and institutional volume. In low-volume centers, variability in results has reinforced skepticism about OPCAB’s reproducibility.

Technical challenges are particularly evident in multivessel disease, where accessing posterior and lateral vessels demands complex positioning maneuvers. Inadequate exposure can compromise graft quality and completeness of revascularization [42]. These difficulties have limited OPCAB’s appeal among surgeons who are more comfortable with the controlled environment of cardiopulmonary bypass.

Simulation and structured training programs have mitigated some of these challenges, but widespread adoption remains constrained by the need for specialized expertise. Without consistent exposure during training, many surgeons lack confidence in performing OPCAB safely across diverse patient populations [43].

5.2. Incomplete Revascularization

Concerns about incomplete revascularization have persisted since the introduction of OPCAB. Several trials and registries have reported lower rates of multivessel grafting compared with ONCAB, raising questions about long-term durability [44]. Incomplete revascularization has been linked to higher rates of repeat interventions and adverse outcomes in some studies.

However, experienced centers have demonstrated that complete revascularization is achievable with OPCAB, particularly when stabilization and positioning devices are used effectively [18]. The discrepancy between high-volume and low-volume institutions underscores the importance of surgical expertise.

Incomplete revascularization remains a barrier to universal adoption, as many surgeons perceive OPCAB as less reliable for complex coronary anatomy. Addressing this concern requires both technical innovation and structured training to ensure reproducibility across diverse practice settings. Hybrid coronary revascularization, which combines OPCAB for the left anterior descending artery with percutaneous coronary intervention (PCI) for non-left anterior descending (LAD) lesions, has emerged as a potential strategy to address incomplete revascularization in selected patients [45]. This approach may offer the durability of surgical grafting while leveraging PCI to treat anatomically challenging or diffusely diseased vessels, thereby improving overall completeness of revascularization.

5.3. Variable Outcomes

Outcome variability is another major barrier. While some centers report excellent results with OPCAB, others have documented inferior graft patency and higher rates of repeat revascularization [46]. This inconsistency has fueled debate and limited guideline endorsement.

Variability reflects differences in surgeon experience, institutional resources, and patient selection. In high-volume centers with dedicated OPCAB programs, outcomes are comparable to ONCAB, but in low-volume institutions, results are less predictable [18]. This disparity has reinforced the perception that OPCAB is a niche technique rather than a universally applicable approach.

Reducing variability requires standardization of training, institutional support, and careful patient selection. Without these measures, OPCAB will continue to face skepticism from the broader surgical community.

5.4. Long-Term Graft Patency Concerns

Long-term graft patency remains a critical concern. Angiographic studies have reported slightly lower patency rates in OPCAB compared with ONCAB, particularly in complex multivessel disease [47]. These findings have raised doubts about the durability of OPCAB and its ability to provide equivalent long-term outcomes.

Some studies suggest that patency differences may be attributable to technical factors rather than intrinsic limitations of OPCAB. In experienced hands, graft patency rates are comparable to ONCAB, highlighting the importance of surgical expertise [6].

Nevertheless, concerns about long-term durability persist, particularly among guideline committees and institutions with limited OPCAB experience. Addressing these concerns requires ongoing research, standardized reporting, and long-term follow-up data.

5.5. Mixed Evidence and Trial Design Limitations

The evidence base for OPCAB is complicated by trial design limitations. High crossover rates, surgeon expertise bias, and heterogeneous patient populations have undermined the generalizability of findings [48]. For example, the ROOBY trial reported inferior outcomes with OPCAB, but critics noted that participating surgeons had limited experience, potentially skewing results.

Meta-analyses have attempted to synthesize data, but heterogeneity in trial design and patient selection complicates interpretation (

Table 1. Meta-Analyses of randomized controlled trials comparing off-pump and on-pump CABG.

Author/Year	No. of RCTs	Participants	Endpoint(s)	Key Outcomes
He 2024 [23]	28	16,090	Stroke, long-term mortality	Stroke reduced in OPCAB; higher mid-term coronary reintervention and long-term mortality
Zhou 2022 [33]	16	6227	Overall graft patency	Lower overall and SVG graft patency in OPCAB
Machado 2022 [49]	5	6221	Mortality, stroke, reintervention, renal	Higher short-term reintervention in OPCAB; other outcomes similar
Mauldon 2020 [50]	37	15,324	Short-term mortality, stroke	Stroke reduced in OPCAB; mortality similar
Gaudino 2018 [51]	104	20,626	All-cause mortality (longest follow-up)	Decreased midterm survival in OPCAB
Smart 2018 [52]	6	8145	Long-term mortality, stroke, reintervention	Higher long-term mortality in OPCAB; stroke and reintervention similar
Takagi 2018 [53]	8	8780	Long-term mortality	Increased long-term mortality in OPCAB
Zhou 2018 [54]	11	11,246	Coronary reintervention (short/mid/long-term)	Mid-term reintervention increased in OPCAB; long-term similar
Filardo 2018 [55]	36	13,338	Short-term and late mortality	No difference between OPCAB and ONCAB
Kowalewski 2016 [56]	100	19,192	Short-term mortality, stroke	Stroke reduced in OPCAB; mortality similar
Dieberg 2016 [57]	54	16,261	Short-term mortality, stroke	Stroke trend favouring OPCAB; mortality similar
Deppe 2016 [58]	51	16,904	Mortality, stroke, reintervention, renal	Stroke and renal impairment higher in ONCAB; reintervention higher in OPCAB
Luo 2015 [59]	7	9128	Mortality, stroke, renal failure, reintervention	No significant differences
Zhang 2014 [60]	12	4711	Overall graft patency	SVG occlusion lower in ONCAB; LIMA/Radial similar
Takagi 2014 [61]	8	10,954	Mid-term MACCE	No increase in MACCE with OPCAB
Takagi 2014 [62]	5	1486	Long-term mortality	Trend toward increased long-term mortality in OPCAB
Chaudhry 2014 [63]	3	879	Mid- and long-term mortality	Mortality comparable between OPCAB and ONCAB
Zhang 2013 [64]	9	10,459	Mid-term mortality	No increase in mid-term mortality with OPCAB
Takagi 2013 [65]	12	11,594	Coronary reintervention (>1 year)	Higher reintervention rates in OPCAB
Sun 2012 [66]	13	2326	Cognitive dysfunction	Early cognitive dysfunction reduced in OPCAB
Sa 2012 [67]	47	13,524	Mortality, stroke	Stroke reduced in OPCAB; mortality similar
Chen 2012 [68]	43	16,828	AF, MI, Stroke	No significant difference in stroke and MI; reduced AF after OPCAB
Afilalo 2012 [69]	59	8961	Mortality, stroke	Stroke reduced in OPCAB; mortality similar
Takagi 2010 [70]	8	3702	Graft patency (>3 months)	Higher graft occlusion in OPCAB
Takagi 2010 [71]	12	4326	Late mortality (>1 year)	Increased late mortality in OPCAB
Seabra 2010 [72]	22	4819	AKI, dialysis requirement	AKI reduced in OPCAB; dialysis similar
Feng 2009 [73]	10	1018	Mid-term mortality, stroke, reintervention	No significant differences
Takagi 2008 [74]	9	1012	Cognitive outcomes	Early cognitive benefit in OPCAB; not sustained
Moller 2008 [75]	66	5537	Mortality, stroke, reintervention	No significant differences
Marasco 2008 [24]	8	892	Cognitive outcomes	No convincing differences
Takagi 2007 [76]	32	3714	Stroke	No reduction in stroke with OPCAB
Takagi 2007 [77]	8	811	Cognitive outcomes	Early benefit in OPCAB; not sustained
Parolari 2005 [78]	5	1105	Graft patency	Lower graft patency in OPCAB
Parolari 2003 [79]	9	1090	Major short-term outcomes	Trend toward reduced death/stroke/MI in OPCAB

) [23,24,33,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79]. Registry data provide valuable insights but are subject to confounding and selection bias.

These limitations have contributed to ongoing debate and guideline ambiguity. Without robust, well-designed trials, OPCAB will continue to face skepticism despite promising results in selected populations.

5.6. Surgeon and Team Training and Experience

Surgeon and team experience are central to OPCAB success. Outcomes are consistently superior in high-volume centers, reflecting cumulative expertise and multidisciplinary coordination [18]. Conversely, limited exposure during training programs has constrained adoption in many regions.

Team dynamics are particularly important, as anesthesiologists and perfusionists play critical roles in managing hemodynamics and ensuring patient safety. Institutions that invest in multidisciplinary training report better outcomes and greater confidence in OPCAB [80].

Expanding OPCAB adoption requires structured curricula, simulation platforms, and mentorship programs. Without these investments, variability in outcomes will persist, reinforcing skepticism about OPCAB’s reproducibility.

5.7. Institutional and Resource Barriers

Institutional resources also influence adoption. OPCAB requires specialized stabilization devices, positioning systems, and trained personnel, which may not be available in all centers. Smaller institutions often lack the infrastructure to support OPCAB, limiting its feasibility.

Economic considerations further shape adoption. While OPCAB can reduce costs through shorter hospital stays and fewer complications, these savings may be offset by equipment costs and training requirements. Institutions must weigh these factors when deciding whether to invest in OPCAB programs.

Resource barriers remain a significant obstacle, particularly in low-volume centers and resource-limited settings [37]. Addressing these challenges requires strategic investment and regionalization of expertise.

5.8. Guideline Ambiguity

Guideline ambiguity has reinforced skepticism about OPCAB. While major societies acknowledge its potential benefits in selected patients, they stop short of recommending routine use [31,32]. This cautious stance reflects concerns about variability, incomplete revascularization, and long-term patency.

Ambiguous guidelines create uncertainty for institutions and surgeons, limiting confidence in adopting OPCAB. Clearer recommendations, informed by robust evidence, are needed to support broader integration.

Until guidelines provide stronger endorsement, OPCAB will remain a selective rather than universal strategy.

5.9. Patient Selection Issues

Patient selection is critical to OPCAB success. While high-risk patients may benefit from reduced morbidity, others may derive little advantage compared with ONCAB [19]. Identifying appropriate candidates requires careful assessment of coronary anatomy, comorbidities, and institutional expertise.

Inconsistent patient selection has contributed to variability in outcomes and skepticism about OPCAB’s reproducibility. Standardized criteria are needed to guide decision-making and ensure consistent results.

Across the available evidence, several high-risk subgroups appear to derive particular benefit from OPCAB. These include elderly patients, especially those over 75 years; individuals with significant aortic calcification or a ‘porcelain aorta,’ in whom avoiding aortic manipulation reduces embolic risk; patients with advanced chronic kidney disease, who may be more vulnerable to CPB-associated renal injury; those with impaired left ventricular function; and individuals with multiple comorbidities such as diabetes, peripheral vascular disease, or frailty [36]. These readily identifiable clinical variables can help guide patient selection in settings where minimizing perioperative risk is a priority.

Ultimately, patient selection remains both a barrier and an opportunity. With appropriate criteria, OPCAB can deliver meaningful benefits, but without them, outcomes will remain inconsistent.

6. Future Directions

6.1. Robotic and Minimally Invasive OPCAB

Robotic and minimally invasive approaches represent the next frontier in OPCAB. Robotic platforms allow enhanced visualization, precision, and dexterity, enabling surgeons to perform coronary anastomoses through small thoracic incisions without sternotomy [81]. These techniques aim to reduce surgical trauma, accelerate recovery, and improve cosmetic outcomes while maintaining the physiological benefits of off-pump surgery.

Early experiences with robotic OPCAB have demonstrated feasibility and safety, with promising short-term outcomes in selected patients [82]. Minimally invasive OPCAB, performed through limited thoracotomies, has also gained traction, particularly for single-vessel or minimally complex disease. These approaches reduce postoperative pain, shorten hospital stays, and may lower infection risk [83].

However, widespread adoption is limited by technical challenges, steep learning curves, and the need for specialized equipment. Robotic OPCAB requires significant institutional investment and surgeon training, while minimally invasive approaches demand advanced positioning and stabilization techniques [84]. As technology evolves, integration of robotic assistance with OPCAB may expand its role, particularly in centers committed to innovation and training.

6.2. Role in Hybrid Revascularization Strategies

Hybrid revascularization strategies combine surgical and percutaneous approaches to optimize outcomes. OPCAB plays a central role in these strategies, particularly when used to graft the left internal mammary artery (LIMA) to the LAD, while PCI addresses non-LAD lesions [85]. This approach leverages the durability of surgical grafts with the minimally invasive nature of PCI.

Comparative evidence between surgical and percutaneous revascularization provides additional context for the role of OPCAB and ONCAB. Long-term follow-up from the Octopus randomized trials demonstrates that OPCAB and PCI achieve similar 20-year survival, although OPCAB is associated with significantly fewer repeat revascularizations [86]. Stroke outcomes are also comparable between OPCAB and PCI, as shown in the CREDO-Kyoto registry [87]. In contrast, the SYNTAXES 10-year analysis confirms that ONCAB provides superior long-term survival compared with PCI in patients with complex multivessel or left main disease [88]. A recent network meta-analysis further indicates that all surgical techniques—including OPCAB, OPCAB with proximal anastomotic device, and anaortic OPCAB—achieve more complete revascularization than PCI, with anaortic OPCAB offering the lowest stroke risk [89]. These findings highlight how the distinct strengths of surgical and percutaneous revascularization can be combined, providing a conceptual foundation for the use of OPCAB as the surgical component within hybrid revascularization strategies.

Hybrid revascularization is particularly advantageous in complex or high-risk patients, where combining an off-pump LIMA–LAD graft with PCI to non-LAD vessels can provide a rapid, reproducible, and physiologically gentle approach. This strategy avoids aortic manipulation—critical in patients with porcelain aorta—while reducing operative stress in frail or comorbid individuals. By pairing the durability of the LIMA–LAD anastomosis with the flexibility of PCI for multivessel disease, hybrid revascularization offers a safe and effective solution for very sick or anatomically challenging patients, complementing the strengths of both OPCAB and percutaneous techniques.

Hybrid strategies are particularly attractive for patients with multivessel disease who may benefit from reduced surgical trauma and shorter recovery times. Studies have demonstrated comparable outcomes to conventional CABG, with reduced hospital stays and faster return to daily activities [90].

OPCAB is well suited to hybrid approaches, as it avoids cardiopulmonary bypass and facilitates minimally invasive access. The combination of OPCAB and PCI may provide a balanced solution for patients with complex coronary anatomy, offering both durability and reduced morbidity [91].

Challenges include coordination between surgical and interventional teams, timing of procedures, and management of dual antiplatelet therapy. Nevertheless, hybrid revascularization represents a promising avenue for integrating OPCAB into contemporary practice.

6.3. Research Priorities and Trial Design

Future research must address the limitations of existing evidence. Many trials have been criticized for high crossover rates, limited surgeon experience, and heterogeneous patient populations, which undermine generalizability [92]. Designing robust trials with standardized training requirements and stratified patient selection is essential to clarify OPCAB’s role.

Long-term graft patency remains a critical research priority. Studies should incorporate angiographic and imaging follow-up to assess durability across diverse patient populations. Additionally, neurocognitive outcomes and quality of life measures warrant further investigation, as these may represent meaningful advantages of OPCAB not captured by traditional endpoints.

Economic analyses are also needed to evaluate cost-effectiveness in different healthcare systems. Comparative studies across high- and low-volume centers could clarify the impact of institutional expertise on outcomes and resource utilization.

Finally, integration of emerging technologies such as robotics, artificial intelligence, and advanced simulation into OPCAB research will be essential. These innovations may reduce technical barriers, improve reproducibility, and expand the applicability of OPCAB in the coming decades [93].

7. Conclusions

OPCAB has evolved from a technically challenging innovation into a mature surgical technique supported by advances in stabilization devices, anesthetic management, and structured training. Evidence from randomized controlled trials, meta-analyses, and registries demonstrates that OPCAB achieves comparable early mortality to conventional ONCAB, with potential advantages in reducing perioperative morbidity, particularly renal dysfunction and neurological complications. These benefits appear most pronounced in high-risk populations such as elderly patients and those with significant comorbidities. However, concerns regarding incomplete revascularization, variable outcomes across institutions, and long-term graft patency continue to limit universal adoption.

Global practice variation underscores the influence of surgical training, institutional resources, and guideline perspectives. Regions with structured training programs and high-volume centers report excellent outcomes, while low-volume institutions often struggle with reproducibility. This disparity highlights the importance of surgeon and team expertise, as well as the need for standardized curricula and simulation platforms to ensure consistent quality.

Future directions, including robotic and minimally invasive OPCAB, hybrid revascularization strategies, and integration of emerging technologies, hold promise for expanding the role of OPCAB. Nevertheless, robust trial design, long-term follow-up, and comprehensive cost-effectiveness analyses remain essential to clarify its place in contemporary practice.

In summary, OPCAB should not be viewed as a universal replacement for ONCAB, but rather as a complementary technique with distinct advantages in selected patient populations. A balanced, evidence-based approach that integrates OPCAB into surgical practice according to patient risk profiles, institutional expertise, and evolving technological innovations offers the most rational path forward. By aligning technical evolution with rigorous clinical evidence, OPCAB can continue to contribute meaningfully to the advancement of coronary revascularization.